Dataset Information

Cardiovascular outcomes in patients with diabetes when initiating blood pressure lowering at baseline SBP between 130 and 140 mm Hg: A meta-analysis.

ABSTRACT: The efficacy and safety of blood pressure (BP) lowering initiated at baseline systolic BP (SBP) of 130-140 mm Hg in patients with diabetes remain controversial. The authors aimed to investigate the benefits and harms of BP lowering initiated at these levels for patients with diabetes. Medline and EMBASE were searched from inception to March 10, 2018. The primary outcome was major cardiovascular events. Random-effects model was used to pool all the estimates. Six trials with 21 574 diabetics were included. In diabetics, initiating BP lowering at baseline SBP of 130 and 140 mm Hg did not reduce the rate of major cardiovascular events (RR, 1.01 [95% CI, 0.93-1.10]), finding that was consistent in subgroup and sensitivity analyses. Moreover, BP lowering did not reduce the risks of myocardial infarction (RR, 0.99 [95% CI, 0.85-1.16]), stroke (0.83 [95% CI, 0.54-1.27]), heart failure (0.91 [95% CI, 0.79-1.04]), albuminuria (0.93 [95% CI, 0.84-1.04]), end-stage renal disease (0.93 [95% CI, 0.70-1.24]), cardiovascular death (1.25 [95% CI, 0.90-1.74]) and all-cause death (1.05 [95% CI, 0.94-1.17]) in patients with diabetes and baseline SBP of 130-140 mm Hg but possibly increase the risks of serious adverse events (RR, 2.00 [95% CI, 1.33-3.01]) and hypotension (5.30 [95% CI, 0.99-28.40]). In diabetics, initiating BP lowering at baseline SBP of 130-140 mm Hg may not produce any benefit but probably increase the risks of serious adverse events and hypotension. It may not be recommended to initiate BP lowering at a threshold of SBP lower than 140 mm Hg for diabetics.

SUBMITTER: Wang S

PROVIDER: S-EPMC8030568 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Cardiovascular outcomes in patients with diabetes when initiating blood pressure lowering at baseline SBP between 130 and 140 mm Hg: A meta-analysis.

Wang Shifei S Djama Nima Moumin NM Lai Yanxian Y Li Hairui H Liao Wangjun W Liao Yulin Y Bin Jianping J

Journal of clinical hypertension (Greenwich, Conn.) 20190113 2

The efficacy and safety of blood pressure (BP) lowering initiated at baseline systolic BP (SBP) of 130-140 mm Hg in patients with diabetes remain controversial. The authors aimed to investigate the benefits and harms of BP lowering initiated at these levels for patients with diabetes. Medline and EMBASE were searched from inception to March 10, 2018. The primary outcome was major cardiovascular events. Random-effects model was used to pool all the estimates. Six trials with 21 574 diabetics were ...[more]

PMID: 30637947

Similar Datasets

Project description:BackgroundData from before the 2000s indicate that the majority of incident cardiovascular disease (CVD) events occur among US adults with systolic and diastolic blood pressure (SBP/DBP) ≥140/90 mm Hg. Over the past several decades, BP has declined and hypertension control has improved.MethodsWe estimated the percentage of incident CVD events that occur at SBP/DBP <140/90 mm Hg in a pooled analysis of 3 contemporary US cohorts: the REGARDS study (Reasons for Geographic and Racial Differences in Stroke), the MESA (Multi-Ethnic Study of Atherosclerosis), and the JHS (Jackson Heart Study) (n=31 856; REGARDS=21 208; MESA=6779; JHS=3869). Baseline study visits were conducted in 2003 to 2007 for REGARDS, 2000 to 2002 for MESA, and 2000 to 2004 for JHS. BP was measured by trained staff using standardized methods. Antihypertensive medication use was self-reported. The primary outcome was incident CVD, defined by the first occurrence of fatal or nonfatal stroke, nonfatal myocardial infarction, fatal coronary heart disease, or heart failure. Events were adjudicated in each study.ResultsOver a mean follow-up of 7.7 years, 2584 participants had incident CVD events. Overall, 63.0% (95% confidence interval [CI], 54.9-71.1) of events occurred in participants with SBP/DBP <140/90 mm Hg; 58.4% (95% CI, 47.7-69.2) and 68.1% (95% CI, 60.1-76.0) among those taking and not taking antihypertensive medication, respectively. The majority of events occurred in participants with SBP/DBP <140/90 mm Hg among those <65 years of age (66.7%; 95% CI, 60.5-73.0) and ≥65 years of age (60.3%; 95% CI, 51.0-69.5), women (61.4%; 95% CI, 49.9-72.9) and men (63.8%; 95% CI, 58.4-69.1), and for whites (68.7%; 95% CI, 66.1-71.3), blacks (59.0%; 95% CI, 49.5-68.6), Hispanics (52.7%; 95% CI, 45.1-60.4), and Chinese-Americans (58.5%; 95% CI, 45.2-71.8). Among participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg, 76.6% (95% CI, 75.8-77.5) were eligible for statin treatment, but only 33.2% (95% CI, 32.1-34.3) were taking one, and 19.5% (95% CI, 18.5-20.5) met the SPRINT (Systolic Blood Pressure Intervention Trial) eligibility criteria and may benefit from a SBP target goal of 120 mm Hg.ConclusionsAlthough higher BP levels are associated with increased CVD risk, in the modern era, the majority of incident CVD events occur in US adults with SBP/DBP <140/90 mm Hg. While absolute risk and cost-effectiveness should be considered, additional CVD risk-reduction measures for adults with SBP/DBP <140/90 mm Hg at high risk for CVD may be warranted.

Project description:ImportanceExtremely low diastolic blood pressure has been reported to be associated with increased adverse cardiovascular events (ie, the diastolic J-shape phenomenon); however, current US guidelines recommend an intensive blood pressure target of less than 130/80 mm Hg without mentioning the lower limits of diastolic blood pressure.ObjectivesTo evaluate whether there is a diastolic J-shape phenomenon for patients with an treated systolic blood pressure of less than 130 mm Hg and to explore the safe and optimal diastolic blood pressure ranges for this patient population.Design, setting, and participantsThis cohort study analyzed outcome data of patients at high cardiovascular risk who were randomized to intensive or standard blood pressure control and achieved treated systolic blood pressure of less than 130 mm Hg in the Systolic Blood Pressure Intervention Trial (SPRINT) and Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) trial. Data were collected from October 2010 to August 2015 (SPRINT) and from September 1999 to June 2009 (ACCORD-BP). Data were analyzed from January to May 2020.ExposureTreated diastolic blood pressure, divided in intervals of less than 60, 60 to less than 70, 70 to less than 80, and 80 mm Hg and greater.Main outcomes and measuresThe primary outcome was a composite of all-cause death, nonfatal myocardial infarction, and nonfatal stroke. A composite cardiovascular outcome, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, was among the key secondary outcomes.ResultsA total of 7515 patients (mean [SD] age, 65.6 [8.7] years; 4553 [60.6%] men) were included in this analysis. The nominally lowest risk was observed at a diastolic blood pressure between 70 and 80 mm Hg for the primary outcome, the composite cardiovascular outcome, nonfatal myocardial infarction, and cardiovascular death. A mean diastolic blood pressure of less than 60 mm Hg was associated with significantly increased risk of the primary outcome (hazard ratio [HR], 1.46; 95% CI, 1.13-1.90; P = .004), the composite cardiovascular outcome (HR, 1.74; 95% CI, 1.26-2.41; P = .001), nonfatal myocardial infarction (HR, 1.73; 95% CI, 1.15-2.59; P = .008), and nonfatal stroke (HR, 2.67; 95% CI, 1.26-5.63; P = .01).Conclusions and relevanceThis cohort study found that lowering diastolic blood pressure to less than 60 mm Hg was associated with increased risk of cardiovascular events in patients with high cardiovascular risk and an treated systolic blood pressure less than 130 mm Hg. The finding that a diastolic blood pressure value between 70 and 80 mm Hg was an optimum target for this patient population merits further study.

Dataset Information

Cardiovascular outcomes in patients with diabetes when initiating blood pressure lowering at baseline SBP between 130 and 140 mm Hg: A meta-analysis.

Publications

Cardiovascular outcomes in patients with diabetes when initiating blood pressure lowering at baseline SBP between 130 and 140 mm Hg: A meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets